Acquisition - June 9, 2016
Probi acquires Nutraceutix
Probi to acquire Nutraceutix, strongly expanding its North American presence and capabilities, and announces rights issue of ca SEK 600 million. Swedish Probi has announced that its US subsidiary Probi USA has signed an asset purchase agreement under which Probi will acquire the operations of the US probiotic company TNTGamble, doing business as Nutraceutix, for a preliminary cash purchase price […]
Acquisition - October 29, 2015
Probi signs deal with Seoul Milk for probiotic strains
Swedish Probi has signed a deal with Korean Seoul Milk to include probiotic strains in their dairy products. The biotech company Probi signs a licensing and supply deal with the Korean dairy producer Seoul Milk. This is the first time Probi signs a deal for probiotic dairy products. Probi’s probiotic strain LP299V will be included […]
New Market - October 14, 2014
Probi to launch Probi Digestis in Brazil
Probi has signed a distribution agreement with Laboratório Daudt, the oldest Brazilian pharmaceutical company with market presence since 130 years. Following registration, Lab. Daudt plans to launch Probi Digestis during 2015. Probi AB and Lab. Daudt have agreed to launch the probiotic supplement – Probi Mage – on the Brazilian market. “Key to success in such a […]
Collaboration - September 26, 2014
Probi expands collaboration
Probi and Pharmavite expand collaboration in the US and international markets. The two companies have signed a new long-term agreement for distribution and marketing of Probi’s probiotic products. Pharmavite launched Probi Digestis capsules based on Probi’s flagship strain LP299V in the US market under the Nature Made brand in 2012 and have accounted for a significant portion of Probi’s […]
Pharma Business - January 15, 2014
Symrise has increased its shareholding in Probi to 30.03%
Symrise has increased its shareholding in Probi to 30.03% which gives rise to an obligation to launch a mandatory public offer. Probi has been informed that on 10 January 2014 Symrise AG (“Symrise”) acquired 11,010 shares in Probi AB (publ) (“Probi” or “the company”), which is listed on Nasdaq OMX Stockholm, whereby Symrise holds 2,812,505 […]
In a new job - November 20, 2013
Probi appoints new CEO
Swedish biotechnology company Probi has appointed Peter Nählstedt as its new CEO. Peter Nählstedt has extensive experience from the international life science industry through various executive positions involving strategy, marketing and sales at GE Healthcare Life Science, states the company in a press release. Peter Nählstedt joins Probi from Trelleborg Marine Systems where he has […]
